TAKE Solutions Limited (BOM:532890)
India · Delayed Price · Currency is INR 10.55
-0.21 (-1.95%)
At close: Jul 29, 2025
Theseus Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | - | - | 656.08 | 1,891 | 6,526 | 7,740 | Upgrade |
Other Revenue | - | - | - | - | - | 0.01 | Upgrade |
| - | - | 656.08 | 1,891 | 6,526 | 7,740 | Upgrade | |
Revenue Growth (YoY) | - | - | -65.30% | -71.03% | -15.68% | -65.02% | Upgrade |
Cost of Revenue | 9.23 | 10.95 | 437.08 | 1,403 | 5,166 | 6,824 | Upgrade |
Gross Profit | -9.23 | -10.95 | 219 | 487.41 | 1,360 | 916.54 | Upgrade |
Selling, General & Admin | - | - | 26.94 | 26.55 | 53.85 | 139.02 | Upgrade |
Other Operating Expenses | 51.01 | 63.8 | 320.25 | 649.75 | 1,205 | 1,446 | Upgrade |
Operating Expenses | 51.35 | 64.25 | 425.94 | 844.7 | 2,015 | 2,739 | Upgrade |
Operating Income | -60.58 | -75.2 | -206.94 | -357.29 | -655.23 | -1,822 | Upgrade |
Interest Expense | -16.49 | -19.61 | -54.31 | -70.96 | -270.36 | -294.63 | Upgrade |
Interest & Investment Income | - | - | 4.94 | 8.3 | 7.29 | 9.01 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 4.04 | 55.74 | 67.56 | -61.87 | Upgrade |
Other Non Operating Income (Expenses) | 102.6 | 102.19 | 6.75 | 12.91 | 70.68 | 31.43 | Upgrade |
EBT Excluding Unusual Items | 25.53 | 7.38 | -245.52 | -351.3 | -780.06 | -2,138 | Upgrade |
Impairment of Goodwill | - | - | -522.91 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.78 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -6.55 | 2.47 | 0.01 | 0.28 | Upgrade |
Other Unusual Items | - | - | -408.92 | -103.9 | - | -2,251 | Upgrade |
Pretax Income | 25.53 | 7.38 | -1,184 | -452.73 | -780.05 | -4,388 | Upgrade |
Income Tax Expense | -0.57 | - | 12.3 | 16.8 | 48.45 | 135.51 | Upgrade |
Earnings From Continuing Operations | 26.1 | 7.38 | -1,196 | -469.53 | -828.5 | -4,523 | Upgrade |
Earnings From Discontinued Operations | 376.95 | 367.29 | - | -534.01 | -6,994 | 14 | Upgrade |
Net Income to Company | 403.05 | 374.67 | -1,196 | -1,004 | -7,823 | -4,509 | Upgrade |
Minority Interest in Earnings | - | - | - | 0.89 | 0.41 | -10.79 | Upgrade |
Net Income | 403.05 | 374.67 | -1,196 | -1,003 | -7,823 | -4,520 | Upgrade |
Net Income to Common | 403.05 | 374.67 | -1,196 | -1,003 | -7,823 | -4,520 | Upgrade |
Shares Outstanding (Basic) | 148 | 146 | 146 | 146 | 146 | 146 | Upgrade |
Shares Outstanding (Diluted) | 148 | 146 | 146 | 146 | 146 | 146 | Upgrade |
Shares Change (YoY) | 2.01% | 0.09% | - | -0.00% | - | - | Upgrade |
EPS (Basic) | 2.72 | 2.56 | -8.18 | -6.86 | -53.50 | -30.91 | Upgrade |
EPS (Diluted) | 2.72 | 2.56 | -8.18 | -6.86 | -53.50 | -30.91 | Upgrade |
Free Cash Flow | - | -163.66 | 14 | -123.81 | 890.99 | 1,321 | Upgrade |
Free Cash Flow Per Share | - | -1.12 | 0.10 | -0.85 | 6.09 | 9.03 | Upgrade |
Gross Margin | - | - | 33.38% | 25.78% | 20.84% | 11.84% | Upgrade |
Operating Margin | - | - | -31.54% | -18.90% | -10.04% | -23.54% | Upgrade |
Profit Margin | - | - | -182.33% | -53.03% | -119.86% | -58.40% | Upgrade |
Free Cash Flow Margin | - | - | 2.13% | -6.55% | 13.65% | 17.07% | Upgrade |
EBITDA | -69.7 | -74.75 | -168.21 | -249.56 | -26.91 | -1,013 | Upgrade |
EBITDA Margin | - | - | -25.64% | -13.20% | -0.41% | -13.09% | Upgrade |
D&A For EBITDA | -9.12 | 0.45 | 38.73 | 107.73 | 628.32 | 808.99 | Upgrade |
EBIT | -60.58 | -75.2 | -206.94 | -357.29 | -655.23 | -1,822 | Upgrade |
EBIT Margin | - | - | -31.54% | -18.90% | -10.04% | -23.54% | Upgrade |
Revenue as Reported | 102.6 | 102.19 | 671.81 | 1,975 | 6,694 | 7,860 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.